ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.91), $0.02 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $3.87 million versus the consensus estimate of $3.84 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.